Patient characteristics according to disease group
| Characteristic, n (%) . | Disease group . | |||||
|---|---|---|---|---|---|---|
| Combined* . | AML . | ALL . | Lymphoma . | CML . | MDS . | |
| n | 2566 | 761 | 322 | 254 | 646 | 371 |
| Age (y), median (range) | 42.4 (0.6-74.5) | 43.2 (1.0-74.5) | 23.7 (0.6-63.8) | 39.6 (0.9-67.0) | 43.9 (3.0-69.6) | 50.7 (1.2-72.6) |
| Age (y) | ||||||
| 0-18 | 260 (10%) | 74 (10%) | 124 (39%) | 5 (2%) | 32 (5%) | 23 (6%) |
| 19-40 | 853 (33%) | 219 (29%) | 135 (42%) | 92 (36%) | 298 (46%) | 64 (17%) |
| ≥41 | 1453 (57%) | 443 (58%) | 63 (20%) | 157 (62%) | 316 (49%) | 284 (77%) |
| Donor age (y) | ||||||
| 0-40 | 1028 (40%) | 293 (39%) | 168 (52%) | 110 (43%) | 295 (46%) | 117 (32%) |
| ≥41 | 1070 (42%) | 317 (42%) | 82 (25%) | 117 (46%) | 235 (36%) | 190 (51%) |
| Unknown | 468 (18%) | 151 (20%) | 72 (22%) | 27 (11%) | 116 (18%) | 64 (17%) |
| Race | ||||||
| White | 2130 (83%) | 622 (82%) | 250 (78%) | 223 (88%) | 535 (83%) | 317 (85%) |
| Other/unknown | 436 (17%) | 139 (18%) | 72 (22%) | 31 (12%) | 111 (17%) | 54 (15%) |
| Donor race | ||||||
| White | 1504 (59%) | 414 (54%) | 175 (54%) | 146 (57%) | 410 (63%) | 222 (60%) |
| Other | 300 (12%) | 91 (12%) | 41 (13%) | 23 (9%) | 91 (14%) | 32 (9%) |
| Unknown | 762 (30%) | 256 (34%) | 106 (33%) | 85 (33%) | 145 (22%) | 117 (32%) |
| Male sex | 1482 (58%) | 403 (53%) | 202 (63%) | 152 (60%) | 382 (59%) | 206 (56%) |
| Donor male sex | 1439 (56%) | 429 (56%) | 170 (53%) | 134 (53%) | 363 (56%) | 216 (58%) |
| Sex mismatch | ||||||
| Female donor/male recipient | 622 (24%) | 168 (22%) | 98 (30%) | 68 (27%) | 154 (24%) | 82 (22%) |
| Other | 1944 (76%) | 593 (78%) | 224 (70%) | 186 (73%) | 492 (76%) | 289 (78%) |
| HLA | ||||||
| Matched, related | 1117 (44%) | 333 (44%) | 100 (31%) | 143 (56%) | 244 (38%) | 164 (44%) |
| Mismatched, related | 170 (7%) | 64 (8%) | 31 (10%) | 13 (5%) | 37 (6%) | 21 (6%) |
| Matched, unrelated | 999 (39%) | 288 (38%) | 146 (45%) | 69 (27%) | 271 (42%) | 160 (43%) |
| Mismatched, unrelated | 244 (10%) | 63 (8%) | 39 (12%) | 17 (7%) | 92 (14%) | 26 (7%) |
| Haploidentical | 32 (1%) | 12 (2%) | 6 (2%) | 10 (4%) | 1 (0%) | 0 (0%) |
| Unknown | 4 (0%) | 1 (0%) | 0 (0%) | 2 (1%) | 1 (0%) | 0 (0%) |
| Myeloablative conditioning | 2138 (83%) | 659 (87%) | 303 (94%) | 110 (43%) | 646 (100%) | 349 (94%) |
| CMV risk | ||||||
| D−/R− | 897 (35%) | 236 (31%) | 122 (38%) | 93 (37%) | 257 (40%) | 126 (34%) |
| D+/R− | 365 (14%) | 109 (14%) | 51 (16%) | 38 (15%) | 86 (13%) | 51 (14%) |
| D−/R+ | 632 (25%) | 215 (28%) | 80 (25%) | 62 (24%) | 134 (21%) | 84 (23%) |
| D+/R+ | 672 (26%) | 201 (26%) | 69 (21%) | 61 (24%) | 169 (26%) | 110 (30%) |
| Cell source PBSC | 1330 (52%) | 460 (60%) | 145 (45%) | 211 (83%) | 117 (18%) | 220 (59%) |
| Ex vivo T-cell depletion | 115 (4%) | 39 (5%) | 10 (3%) | 4 (2%) | 19 (3%) | 37 (10%) |
| Transplantation year | ||||||
| January 1995 to November 1998 | 931 (36%) | 241 (32%) | 130 (40%) | 61 (24%) | 349 (54%) | 111 (30%) |
| December 1998 to May 2002 | 821 (32%) | 220 (29%) | 93 (29%) | 81 (32%) | 210 (33%) | 128 (35%) |
| June 2002 to December 2005 | 814 (32%) | 300 (39%) | 99 (31%) | 112 (44%) | 87 (13%) | 132 (36%) |
| Disease risk | ||||||
| Low | 1136 (44%) | 899 (43%) | 217 (67%) | 234 (92%) | 77 (12%) | 87 (23%) |
| Intermediate | 245 (10%) | 99 (5%) | — | — | 94 (15%) | — |
| High | 1175 (46%) | 1070 (52%) | 105 (33%) | 17 (7%) | 475 (74%) | 284 (77%) |
| Missing | 10 (0%) | 9 (0%) | 0 (0%) | 3 (1%) | 0 (0%) | 0 (0%) |
| AML cytogenetic risk | ||||||
| Favorable | — | 62 (8%) | — | — | — | — |
| Intermediate | — | 393 (52%) | — | — | — | — |
| Adverse | — | 154 (20%) | — | — | — | — |
| Missing | — | 151 (20%) | — | — | — | — |
| GVHD prophylaxis | ||||||
| Calcineurin + MTX | 38 (1%) | 9 (1%) | 2 (1%) | 12 (5%) | 6 (1%) | 2 (1%) |
| Calcineurin only | 489 (19%) | 146 (19%) | 25 (8%) | 133 (52%) | 6 (1%) | 39 (11%) |
| Calcineurin + MMF | 1951 (76%) | 581 (76%) | 280 (87%) | 88 (35%) | 617 (96%) | 324 (87%) |
| Other | 88 (3%) | 25 (3%) | 15 (5%) | 21 (8%) | 17 (3%) | 6 (2%) |
| Acute GVHD | ||||||
| Grade 0-1 | 565 (22%) | 173 (23%) | 48 (15%) | 73 (29%) | 131 (20%) | 87 (23%) |
| Grade 2 | 1412 (55%) | 385 (51%) | 198 (61%) | 122 (48%) | 387 (60%) | 204 (55%) |
| Grade 3-4 | 570 (22%) | 197 (26%) | 75 (23%) | 56 (22%) | 127 (20%) | 80 (22%) |
| Missing | 19 (1%) | 6 (1%) | 1 (0%) | 3 (1%) | 1 (0%) | 0 (0%) |
| Chronic GVHD | 1371 (53%) | 353 (46%) | 167 (52%) | 140 (55%) | 377 (58%) | 210 (57%) |
| Cumulative incidence of CMV by day 100 (95% CI) | ||||||
| Any AG | 36.1 (34-38) | 35.9 (33-39) | 29.9% (25-35) | 34.3% (28-40) | 38.1% (34- 42) | 38.3 (33-43) |
| AG ≥ 10 | 11.6 (10-13) | 9.9 (8-12) | 9.9% (7-13) | 10.6% (7-14) | 16.9% (14-20) | 9.4 (7-12) |
| 2 consecutive AG ≥ 10 | 6.0 (5-7) | 4.9 (3-6) | 4.7% (2-7) | 4.3% (2-7) | 9.0% (7-11) | 5.1 (3-7) |
| Characteristic, n (%) . | Disease group . | |||||
|---|---|---|---|---|---|---|
| Combined* . | AML . | ALL . | Lymphoma . | CML . | MDS . | |
| n | 2566 | 761 | 322 | 254 | 646 | 371 |
| Age (y), median (range) | 42.4 (0.6-74.5) | 43.2 (1.0-74.5) | 23.7 (0.6-63.8) | 39.6 (0.9-67.0) | 43.9 (3.0-69.6) | 50.7 (1.2-72.6) |
| Age (y) | ||||||
| 0-18 | 260 (10%) | 74 (10%) | 124 (39%) | 5 (2%) | 32 (5%) | 23 (6%) |
| 19-40 | 853 (33%) | 219 (29%) | 135 (42%) | 92 (36%) | 298 (46%) | 64 (17%) |
| ≥41 | 1453 (57%) | 443 (58%) | 63 (20%) | 157 (62%) | 316 (49%) | 284 (77%) |
| Donor age (y) | ||||||
| 0-40 | 1028 (40%) | 293 (39%) | 168 (52%) | 110 (43%) | 295 (46%) | 117 (32%) |
| ≥41 | 1070 (42%) | 317 (42%) | 82 (25%) | 117 (46%) | 235 (36%) | 190 (51%) |
| Unknown | 468 (18%) | 151 (20%) | 72 (22%) | 27 (11%) | 116 (18%) | 64 (17%) |
| Race | ||||||
| White | 2130 (83%) | 622 (82%) | 250 (78%) | 223 (88%) | 535 (83%) | 317 (85%) |
| Other/unknown | 436 (17%) | 139 (18%) | 72 (22%) | 31 (12%) | 111 (17%) | 54 (15%) |
| Donor race | ||||||
| White | 1504 (59%) | 414 (54%) | 175 (54%) | 146 (57%) | 410 (63%) | 222 (60%) |
| Other | 300 (12%) | 91 (12%) | 41 (13%) | 23 (9%) | 91 (14%) | 32 (9%) |
| Unknown | 762 (30%) | 256 (34%) | 106 (33%) | 85 (33%) | 145 (22%) | 117 (32%) |
| Male sex | 1482 (58%) | 403 (53%) | 202 (63%) | 152 (60%) | 382 (59%) | 206 (56%) |
| Donor male sex | 1439 (56%) | 429 (56%) | 170 (53%) | 134 (53%) | 363 (56%) | 216 (58%) |
| Sex mismatch | ||||||
| Female donor/male recipient | 622 (24%) | 168 (22%) | 98 (30%) | 68 (27%) | 154 (24%) | 82 (22%) |
| Other | 1944 (76%) | 593 (78%) | 224 (70%) | 186 (73%) | 492 (76%) | 289 (78%) |
| HLA | ||||||
| Matched, related | 1117 (44%) | 333 (44%) | 100 (31%) | 143 (56%) | 244 (38%) | 164 (44%) |
| Mismatched, related | 170 (7%) | 64 (8%) | 31 (10%) | 13 (5%) | 37 (6%) | 21 (6%) |
| Matched, unrelated | 999 (39%) | 288 (38%) | 146 (45%) | 69 (27%) | 271 (42%) | 160 (43%) |
| Mismatched, unrelated | 244 (10%) | 63 (8%) | 39 (12%) | 17 (7%) | 92 (14%) | 26 (7%) |
| Haploidentical | 32 (1%) | 12 (2%) | 6 (2%) | 10 (4%) | 1 (0%) | 0 (0%) |
| Unknown | 4 (0%) | 1 (0%) | 0 (0%) | 2 (1%) | 1 (0%) | 0 (0%) |
| Myeloablative conditioning | 2138 (83%) | 659 (87%) | 303 (94%) | 110 (43%) | 646 (100%) | 349 (94%) |
| CMV risk | ||||||
| D−/R− | 897 (35%) | 236 (31%) | 122 (38%) | 93 (37%) | 257 (40%) | 126 (34%) |
| D+/R− | 365 (14%) | 109 (14%) | 51 (16%) | 38 (15%) | 86 (13%) | 51 (14%) |
| D−/R+ | 632 (25%) | 215 (28%) | 80 (25%) | 62 (24%) | 134 (21%) | 84 (23%) |
| D+/R+ | 672 (26%) | 201 (26%) | 69 (21%) | 61 (24%) | 169 (26%) | 110 (30%) |
| Cell source PBSC | 1330 (52%) | 460 (60%) | 145 (45%) | 211 (83%) | 117 (18%) | 220 (59%) |
| Ex vivo T-cell depletion | 115 (4%) | 39 (5%) | 10 (3%) | 4 (2%) | 19 (3%) | 37 (10%) |
| Transplantation year | ||||||
| January 1995 to November 1998 | 931 (36%) | 241 (32%) | 130 (40%) | 61 (24%) | 349 (54%) | 111 (30%) |
| December 1998 to May 2002 | 821 (32%) | 220 (29%) | 93 (29%) | 81 (32%) | 210 (33%) | 128 (35%) |
| June 2002 to December 2005 | 814 (32%) | 300 (39%) | 99 (31%) | 112 (44%) | 87 (13%) | 132 (36%) |
| Disease risk | ||||||
| Low | 1136 (44%) | 899 (43%) | 217 (67%) | 234 (92%) | 77 (12%) | 87 (23%) |
| Intermediate | 245 (10%) | 99 (5%) | — | — | 94 (15%) | — |
| High | 1175 (46%) | 1070 (52%) | 105 (33%) | 17 (7%) | 475 (74%) | 284 (77%) |
| Missing | 10 (0%) | 9 (0%) | 0 (0%) | 3 (1%) | 0 (0%) | 0 (0%) |
| AML cytogenetic risk | ||||||
| Favorable | — | 62 (8%) | — | — | — | — |
| Intermediate | — | 393 (52%) | — | — | — | — |
| Adverse | — | 154 (20%) | — | — | — | — |
| Missing | — | 151 (20%) | — | — | — | — |
| GVHD prophylaxis | ||||||
| Calcineurin + MTX | 38 (1%) | 9 (1%) | 2 (1%) | 12 (5%) | 6 (1%) | 2 (1%) |
| Calcineurin only | 489 (19%) | 146 (19%) | 25 (8%) | 133 (52%) | 6 (1%) | 39 (11%) |
| Calcineurin + MMF | 1951 (76%) | 581 (76%) | 280 (87%) | 88 (35%) | 617 (96%) | 324 (87%) |
| Other | 88 (3%) | 25 (3%) | 15 (5%) | 21 (8%) | 17 (3%) | 6 (2%) |
| Acute GVHD | ||||||
| Grade 0-1 | 565 (22%) | 173 (23%) | 48 (15%) | 73 (29%) | 131 (20%) | 87 (23%) |
| Grade 2 | 1412 (55%) | 385 (51%) | 198 (61%) | 122 (48%) | 387 (60%) | 204 (55%) |
| Grade 3-4 | 570 (22%) | 197 (26%) | 75 (23%) | 56 (22%) | 127 (20%) | 80 (22%) |
| Missing | 19 (1%) | 6 (1%) | 1 (0%) | 3 (1%) | 1 (0%) | 0 (0%) |
| Chronic GVHD | 1371 (53%) | 353 (46%) | 167 (52%) | 140 (55%) | 377 (58%) | 210 (57%) |
| Cumulative incidence of CMV by day 100 (95% CI) | ||||||
| Any AG | 36.1 (34-38) | 35.9 (33-39) | 29.9% (25-35) | 34.3% (28-40) | 38.1% (34- 42) | 38.3 (33-43) |
| AG ≥ 10 | 11.6 (10-13) | 9.9 (8-12) | 9.9% (7-13) | 10.6% (7-14) | 16.9% (14-20) | 9.4 (7-12) |
| 2 consecutive AG ≥ 10 | 6.0 (5-7) | 4.9 (3-6) | 4.7% (2-7) | 4.3% (2-7) | 9.0% (7-11) | 5.1 (3-7) |
AG, antigenemia.
Combined cohort includes all patients with AML, ALL, lymphoma, CML, and MDS in addition to patients with MM (n = 113), CLL (n = 58), CML receiving reduced intensity conditioning (n = 18), acute leukemia not otherwise specified (n = 20), plasma cell leukemia (n = 2), and acute promyelocytic leukemia (n = 1).